Nektar +9% AH on FDA panel recommendation

|About: Nektar Therapeutics (NKTR)|By:, SA News Editor

Nektar Therapeutics (NKTR) +9.2% AH after a long trading halt, as an FDA advisory panel recommended against requiring cardiovascular outcome trials for a certain class of drugs - including NKTR's Movantik - in the treatment of constipation caused by opioid medicines (earlier).

The drug treatment, being developed by NKTR partner AstraZeneca (AZN), also is being reviewed by health agencies in the European Union and Canada.

The FDA is expected to make a decision on Movantik by Sept. 16.